Strategies That Regulate LSD1 for Novel Therapeutics

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2024 Apr 4

PMID 38572094

Authors

Meng Li

Mengge Dai

Bing Cheng

Shaotong Li

Enhui Guo

Junwei Fu

Ting Ma

Bin Yu

Affiliations

Soon will be listed here.

Abstract

Histone methylation plays crucial roles in regulating chromatin structure and gene transcription in epigenetic modifications. Lysine-specific demethylase 1 (LSD1), the first identified histone demethylase, is universally overexpressed in various diseases. LSD1 dysregulation is closely associated with cancer, viral infections, and neurodegenerative diseases, etc., making it a promising therapeutic target. Several LSD1 inhibitors and two small-molecule degraders (UM171 and BEA-17) have entered the clinical stage. LSD1 can remove methyl groups from histone 3 at lysine 4 or lysine 9 (H3K4 or H3K9), resulting in either transcription repression or activation. While the roles of LSD1 in transcriptional regulation are well-established, studies have revealed that LSD1 can also be dynamically regulated by other factors. For example, the expression or activity of LSD1 can be regulated by many proteins that form transcriptional corepressor complexes with LSD1. Moreover, some post-transcriptional modifications and cellular metabolites can also regulate LSD1 expression or its demethylase activity. Therefore, in this review, we will systematically summarize how proteins involved in the transcriptional corepressor complex, various post-translational modifications, and metabolites act as regulatory factors for LSD1 activity.

References

Cohen P, Frame S . The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001; 2(10):769-76. DOI: 10.1038/35096075. View

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

Welchman R, Gordon C, Mayer R . Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2005; 6(8):599-609. DOI: 10.1038/nrm1700. View

Mimasu S, Sengoku T, Fukuzawa S, Umehara T, Yokoyama S . Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochem Biophys Res Commun. 2007; 366(1):15-22. DOI: 10.1016/j.bbrc.2007.11.066. View

Nicholson T, Chen T . LSD1 demethylates histone and non-histone proteins. Epigenetics. 2009; 4(3):129-32. DOI: 10.4161/epi.4.3.8443. View

Feng J, Li L, Zhang N, Liu J, Zhang L, Gao H . Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms. Oncogene. 2016; 36(20):2775-2790. DOI: 10.1038/onc.2016.432. View

Fourkala E, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R . Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer. 2011; 19(2):137-47. PMC: 3322660. DOI: 10.1530/ERC-11-0310. View

Zhang S, Liu M, Yao Y, Yu B, Liu H . Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacol Res. 2020; 164:105335. DOI: 10.1016/j.phrs.2020.105335. View

Wang D, Liu C, Li H, Tian M, Pan J, Shu G . LSD1 mediates microbial metabolite butyrate-induced thermogenesis in brown and white adipose tissue. Metabolism. 2019; 102:154011. DOI: 10.1016/j.metabol.2019.154011. View

10.

Scoumanne A, Chen X . The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem. 2007; 282(21):15471-5. DOI: 10.1074/jbc.M701023200. View

11.

Liu C, Liu L, Chen X, Cheng J, Zhang H, Zhang C . LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells. Cancer Res. 2017; 78(4):938-949. DOI: 10.1158/0008-5472.CAN-17-1236. View

12.

Ramms B, Pollow D, Zhu H, Nora C, Harrington A, Omar I . Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes. 2022; 71(12):2513-2529. PMC: 9750949. DOI: 10.2337/db21-1131. View

13.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

14.

Anan K, Hino S, Shimizu N, Sakamoto A, Nagaoka K, Takase R . LSD1 mediates metabolic reprogramming by glucocorticoids during myogenic differentiation. Nucleic Acids Res. 2018; 46(11):5441-5454. PMC: 6009677. DOI: 10.1093/nar/gky234. View

15.

Calabrese C, Valentini A, Calabrese G . Gut Microbiota and Type 1 Diabetes Mellitus: The Effect of Mediterranean Diet. Front Nutr. 2021; 7:612773. PMC: 7838384. DOI: 10.3389/fnut.2020.612773. View

16.

Abdel-Magid A . Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Potential Treatment for Different Types of Cancers. ACS Med Chem Lett. 2017; 8(11):1134-1135. PMC: 5683701. DOI: 10.1021/acsmedchemlett.7b00426. View

17.

Doble B, Woodgett J . GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003; 116(Pt 7):1175-86. PMC: 3006448. DOI: 10.1242/jcs.00384. View

18.

Gong Z, Li A, Ding J, Li Q, Zhang L, Li Y . OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis. Adv Sci (Weinh). 2021; 8(15):e2004504. PMC: 8336515. DOI: 10.1002/advs.202004504. View

19.

Song Q, Feng S, Peng W, Li A, Ma T, Yu B . Cullin-RING Ligases as Promising Targets for Gastric Carcinoma Treatment. Pharmacol Res. 2021; 170:105493. DOI: 10.1016/j.phrs.2021.105493. View

20.

Asmamaw M, Liu Y, Zheng Y, Shi X, Liu H . Skp2 in the ubiquitin-proteasome system: A comprehensive review. Med Res Rev. 2020; 40(5):1920-1949. DOI: 10.1002/med.21675. View